Product Pathways - Growth Factors/Cytokines
Human Macrophage Colony Stimulating Factor (hM-CSF) #8929
|8929LC||25 µg (With Carrier)||---||In Stock||---|
|8929LF||25 µg (Carrier Free)||---||In Stock||---|
|8929SF||5 µg (Carrier Free)||---||In Stock||---|
|8929SC||5 µg (With Carrier)||---||In Stock||---|
Recombinant human M-CSF (hM-CSF) Glu33-Ser190 (Accession #P09603-3) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hM-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 18,403. DTT-reduced protein migrates as a 16-26 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 34-40 kDa protein. Heterogeneity in SDS PAGE is due to glycosylation. The expected amino-terminal EEVSE of recombinant hM-CSF was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hM-CSF. All lots are greater than 98% pure.
The bioactivity of recombinant hM-CSF was determined in a M-NFS-60 cell proliferation assay. The ED50 of each lot is between 0.5-2.0 ng/ml.
The purity of recombinant hM-CSF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hM-CSF and staining overnight with Coomassie Blue.
The proliferation of M-NFS-60 cells treated with increasing concentrations of hM-CSF was assessed. After 48 hour treatment with hM-CSF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from M-NFS-60 cells, untreated or treated with hM-CSF for 10 minutes, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (upper) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (lower).
Less than 0.01 ng endotoxin/1 μg hM-CSF.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Macrophage-colony stimulating factor (M-CSF) is produced by fibroblasts, endothelial cells, stromal cells, macrophages, osteoblasts and other cell types (1). M-CSF is required for growth and differentiation of monocytes and macrophages (1,2). M-CSF polarizes macrophages into the M2 phenotype where anti-inflammatory IL-10 is produced, rather than the M1 phenotype where inflammatory cytokines are produced. M-CSF also recruits monocytes and enhances angiogenesis by inducing VEGF production (1,2). M-CSF binds to its receptor (CSF1R); downstream signaling involves PI3K/Akt, ERK and STATs 1, 3, and 5 (1,3). An increase in M-CSF expression may contribute to cancer progression and a higher plasma M-CSF level is associated with rheumatoid arthritis (1,4,5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.